Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04270864
Title Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

colorectal cancer

melanoma

lung non-small cell carcinoma

Advanced Solid Tumor

Therapies

IMO-2125 + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.